Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Two Sigma Investments LP increased its position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 228.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 480,298 shares of the company's stock after acquiring an additional 334,042 shares during the quarter. Two Sigma Investments LP owned about 0.22% of Sana Biotechnology worth $783,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Boxer Capital Management LLC purchased a new stake in Sana Biotechnology during the 4th quarter valued at approximately $2,518,000. Corient Private Wealth LLC grew its holdings in Sana Biotechnology by 161.7% during the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company's stock valued at $1,928,000 after buying an additional 730,699 shares in the last quarter. Millennium Management LLC grew its holdings in Sana Biotechnology by 604.8% during the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after buying an additional 625,481 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Sana Biotechnology by 44.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock valued at $2,538,000 after buying an additional 478,596 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Sana Biotechnology by 1,838.3% during the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company's stock valued at $521,000 after buying an additional 303,318 shares in the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on SANA. Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a report on Tuesday, March 18th. Jefferies Financial Group began coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a "buy" rating and a $7.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Sana Biotechnology in a report on Thursday, April 24th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Sana Biotechnology currently has an average rating of "Moderate Buy" and an average price target of $10.80.

Sana Biotechnology Stock Up 11.4%

Shares of SANA opened at $2.84 on Friday. The company has a market cap of $640.35 million, a PE ratio of -2.03 and a beta of 1.78. The business has a fifty day moving average of $1.84 and a 200 day moving average of $2.33. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $7.40.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. As a group, research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.